Related Experiment Video

Updated: Sep 24, 2025

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.1K

Cytomegalovirus Coinfection in Critically Ill Patients with Novel Coronavirus-2019 Disease: Pathogens or Spectators?

Suhail S Siddiqui1, Soumyadip Chatterjee2, Ambuj Yadav3

  • 1Department of Critical Care Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.

Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine
|May 6, 2022
PubMed

Insights

Cytomegalovirus (CMV) coinfection is an emerging challenge in critically ill patients with Coronavirus disease-2019 (COVID-19). Further research is needed to determine if CMV acts as a pathogen or bystander in these cases.

Area of Science:

  • Virology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • The Coronavirus disease-2019 (COVID-19) pandemic presents unique challenges in patient management.
  • Emergence or reactivation of Herpesviridae family viruses, particularly cytomegalovirus (CMV), is a noted complication.
  • Limited experience exists regarding concomitant viral infections like CMV during COVID-19.

Observation:

  • This case series describes three critically ill patients with COVID-19 and concurrent CMV coinfections.
  • The study originates from India, marking it as the first such case series from the region.
  • The clinical role of CMV in COVID-19 patients remains unclear.

Findings:

  • The presented cases highlight the occurrence of CMV coinfection in severe COVID-19.
  • The interaction between COVID-19 and CMV requires further investigation.
  • Distinguishing between CMV as a bystander or active pathogen is a key research question.

Implications:

  • Understanding CMV's role is crucial for optimizing treatment strategies in COVID-19 patients.
  • This research contributes to the limited global knowledge on viral coinfections during the pandemic.
  • Further studies are warranted to clarify the pathogenicity of CMV in the context of COVID-19.

Keywords:
Coronavirus disease-2019Critically illCytomegalovirusViral coinfection

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K
Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions09:02

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Published on: September 22, 2023

1.6K

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
403
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
358
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
364
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
474
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
219
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
464